De Novo Pharmatech
Focus: De Novo Pharmatech is a Shanghai-based biotech company focused on small molecule and antibody development for oncology indications. The company is early-stage with a lean pipeline in Phase 1 development.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
Open Jobs
0
Recent layoff filing — 84 affected
- 6/18/2025 — Union, MO · 84 affected · Closure
Source: state DOL filings via Big Local News
About De Novo Pharmatech
AI assessmentNot HiringNo open roles listed right now. Follow De Novo Pharmatech to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
2 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
DN1508052-01
Advanced Solid TumorsClinical Trials (1)
NCT03934359A Study to Evaluate the Safety, Tolerability of DN1508052-01 in Advanced Solid Tumors
Phase 1Help build intelligence for De Novo Pharmatech
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.